The longevity-equality dividend: Reshaping women’s career paths
Summary
Rupa Dash argues society and business must rethink careers to unlock the longevity-equality dividend, enabling women to thrive and lead across longer lives.
Contact
Research Information & Knowledge Hub for additional information on IMD publications
Five key insights from necessity entrepreneurs
Summary
There is another entrepreneurial world that is born not from opportunity but from necessity, and it has much to teach us.
Contact
Research Information & Knowledge Hub for additional information on IMD publications
Preparing for the Boardroom - Technology
Summary
Preparing for the Boardroom requires role specific experience, governance insight and credibility. Caroline Basyn explains the pathway for women and in tech.
Contact
Research Information & Knowledge Hub for additional information on IMD publications
Defense industry AI strategy - Energy & Finance
Summary
Defense industry AI strategy offers lessons for energy and finance leaders seeking secure, resilient AI systems aligned with risk, governance, and scale.
Contact
Research Information & Knowledge Hub for additional information on IMD publications
How to identify conflict in your family firm
Summary
As in any conflict resolution, tackling problems in family firms begins by identifying where the problem originates and its precise nature.
Contact
Research Information & Knowledge Hub for additional information on IMD publications
A longevity blueprint for leaders - Movement & Nutrition
Summary
Roland Liebscher-Bracht, Petra Bracht and Christoph Glaser share a three-part formula for daily leadership practice
Contact
Research Information & Knowledge Hub for additional information on IMD publications
The good, the bad, and the ugly: What big energy and utilities players tell us about the new sustainability reporting regime
Summary
An analysis of first-year CSRD and ESRS disclosures shows how mandatory sustainability reporting has improved transparency but diluted strategic insight, based on evidence from energy and utilities companies.
Contact
Research Information & Knowledge Hub for additional information on IMD publications
Oculis: Transforming ophthalmology a drop at a time
Summary
For the team at Oculis, the announcement of the new USD 100 million fundraising could not have come at a more opportune moment. The biopharmaceutical startup was founded in 2017 to transform ophthalmology by developing not only original delivery mechanisms but also groundbreaking treatments for eye diseases like Diabetic Macular Edema (DME). Established by seasoned industry experts, Oculis aimed to replace invasive eye treatments with more accessible, patient-friendly solutions such as topical eye drops. The initial research conducted in a laboratory in Iceland led to a pipeline of drug candidates, now at various stages of clinical testing. The firm continued to ramp up thanks to successive rounds of financing from top investors and partners, totaling more than USD 500 million at the end of 2024. However, it also faced some dramatic events, including the sudden death in early 2024 of its CTO. The company continued to scale, strategically balancing clinical advancements with regulatory milestones. The recent secondary offering on Nasdaq would accelerate the clinical development pipeline, in particular its novel neuroprotective candidate Prisosegtor (OCS-05), OCS-01, a topical eye drop for DME, and OCS-02, a topical biologic eye drop candidate for dry eye disease. Oculis now grappled with a number of strategic decisions, with two questions in particular concerning the team. Should it rely mostly on outsourcing production to a contract development and manufacturing organization (CDMO) or develop its own in-house manufacturing capabilities? There were strong benefits and drawbacks to both approaches. It faced a related dilemma with its product pipeline. Should it continue to rely on its own R&D, as in the past, or should it consider acquiring technologies outside, through M&A activities?
Reference
IMD-2692
Copyright
©2025
Copyright owner
IMD Copyright
Organization
Oculis
Industry
Healthcare, Pharmaceuticals
Available Languages
English
Contact
Research Information & Knowledge Hub for additional information on IMD publications
What I got wrong about board leadership - Jørgen Vig Knudstorp
Summary
Real influence in the boardroom comes not from power or persuasion, but from humility, clarity, and the courage to disagree, says Jørgen Vig Knudstorp
Contact
Research Information & Knowledge Hub for additional information on IMD publications
South Korea’s Innovation Outputs - Competitiveness
Summary
South Korea’s innovation outputs are failing to translate into higher levels of competitiveness. Here’s how other innovation-driven economies can take heed
Contact
Research Information & Knowledge Hub for additional information on IMD publications